Search the Newsreel

3 Reasons Why Growth Investors Shouldn't Overlook RBC Bearings (RBC)

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all. That's because, these stocks usually carry above-average risk and volatility. …

Barinthus Biotherapeutics (Nasdaq: BRNS) details Q2 loss, cash and Clywedog merger plan

Barinthus Biotherapeutics (BRNS) reported a Q2 2026 net loss of $10.6 million and a six-month net loss of $16.1 million, improvements over the prior year due to reduced R&D and administrative expenses. The company holds $59.6 million in cash, expected to fund operations for …

NRB Bearings Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised

RBC Bearings Inc (RBC) Stock News Today

This page provides current stock news for RBC Bearings Inc (RBC), including its latest earnings report. The stock closed at $568.245, up 0.29%, with a market cap of $17.96 billion and a P/E TTM of 62.20. The recent earnings report highlighted that aerospace growth …

Bank of Marin Bancorp (BMRC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Bank of Marin Bancorp (BMRC), highlighting its current earnings forecast score, average price target, and analyst ratings. It indicates that the company ranks 232 out of 395 in the Banking Services industry with a "Hold" signal from …

BioMarin Pharmaceutical Inc (BMRN) Aktuelle Aktien-News

Biomarin Pharmaceutical Inc. - Registered Shares (BMRN) News, Articles, Events & Latest Updates

BioMarin Pharmaceutical Inc. (BMRN) has reported strong Q2 2026 earnings, surpassing estimates in both revenue and profit, driven by significant sales growth and an increased 2026 outlook. The company also announced an early research collaboration with n-Lorem Foundation and the FDA's acceptance of its …

Amarin Corporation PLC (AMRN) Stock News Today

Beng Kuang Marine Limited Provides Earnings Guidance for the Second Half of 2026

Notícias das Ações da BioMarin Pharmaceutical Inc (BMRN)

OneWater Marine Inc (ONEW) Earnings Forecast: Future EPS & Revenue Growth Estimates

Barings BDC Inc (BBDC) Stock News Today

Menon Bearings shareholders approve FY26 results and interim dividend

BioMarin Pharmaceutical Inc (BMRN) (Q2 2026) Earnings Call Highlights: Record Revenue and ...

BioMarin Pharmaceutical (BMRN) Could Be 30% Below Fair Value On Raised Guidance

3 Reasons We Love RBC Bearings (RBC)

This article highlights three key reasons to appreciate RBC Bearings (RBC): its strong revenue growth, outstanding long-term EPS growth, and excellent free cash flow margin. Despite recent underperformance compared to the S&P 500, these financial metrics suggest RBC is a high-quality industrial company with …

MarineMax | 8-K: Current report

This article is a brief notification regarding MarineMax's 8-K filing, which is a Current Report. The content indicates that the filing itself constitutes the complete document.

Bank of Marin Bancorp To Go Ex-Dividend On August 6th, 2026 With 0.25 USD Dividend Per Share

Bank of Marin Bancorp (NASDAQ:BMRC) is scheduled to go ex-dividend on August 6th, 2026, with a dividend payment of $0.25 per share. Shareholders who own BMRC stock before this date will be eligible for the dividend. The ex-dividend date is crucial for investors as …

Bank of Marin Bancorp Q2 2026: Revenue $30.8M, EPS $0.58— 10-Q Summary

Bank of Marin Bancorp (BMRC) reported its Q2 2026 results, showing a significant turnaround with net income of $9.25 million and diluted EPS of $0.58, compared to a loss in the prior year. This improvement was driven by higher net interest income, improved net …

Earnings call transcript: Barings BDC tops Q2 2026 estimates as shares rise

Barings BDC (BBDC) surpassed Q2 2026 earnings and revenue estimates, reporting $0.28 EPS against a $0.25 forecast and $65.2 million in revenue versus an expected $60.88 million. The company covered its $0.26 quarterly dividend, maintained leverage within target, and saw its shares rise 2.26% …

Biomarin Pharma earnings beat by $0.25, revenue topped estimates

Biomarin Pharma (NASDAQ: BMRN) reported strong second-quarter results, beating analyst estimates for both earnings per share (EPS) and revenue. The company posted an EPS of $1.20, exceeding the $0.95 consensus, and revenue of $990 million, higher than the $939.37 million estimate. Its stock has …

Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics

Informe de resultados de BioMarin Q2 2026: supera previsiones y mejora perspectivas

Bank of Marin FY26 Q2 net income rises 8.65% to USD 9.25 million; diluted EPS climbs to USD 0.58

Bank of Marin Bancorp reported an 8.65% increase in GAAP net income to $9.25 million for FY26 Q2, with diluted EPS rising to $0.58. The bank saw a 1.58% rise in net interest income and a 14 basis point widening of its tax-equivalent net …

Barings BDC Reports Strong Q2 Results, Increases Dividend

Barings BDC reported strong Q2 2026 results, with total investment income of $65.2 million and net investment income of $29.0 million, or $0.28 per share, exceeding its dividend. The company's investment portfolio grew to $2.46 billion, maintaining stable leverage, and its board declared a …

BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates

Form 8K Caring Brands Inc For: 6 August By Investing.com

Investing.com reported that Caring Brands Inc. filed a Form 8K on August 6th. The article is a brief announcement about this financial filing, indicating it was published by Investing.com UK.

BioMarin Pharmaceutical (NASDAQ:BMRN) Delivers Impressive Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations

BioMarin Pharmaceutical: Non-GAAP-Gewinn je Aktie sinkt im Q2, Umsatz steigt; Prognose für 2026 angehoben

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q2 revenue up, profit down after Amicus acquisition

BioMarin Pharmaceutical Inc. reported a significant increase in Q2 2026 total revenues to $989.7 million, up from $825.4 million in 2025, primarily due to strong performance from VOXZOGO, PALYNZIQ, and newly acquired products GALAFOLD and POMBILITI + OPFOLDA. Despite revenue growth, net income fell …

BIOMARIN PHARMACEUTICAL ($BMRN) Releases Q2 2026 Earnings, Stock Rises

BioMarin Pharmaceutical Inc. presenta sus previsiones de resultados para el tercer y cuarto trimestre de 2026

Caring Brands Provides Intellectual Property Portfolio Update

Caring Brands Inc. announced an update on its intellectual property portfolio, which now includes five issued U.S. patents. These patents cover two key product platforms

Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q2 Adjusted EPS $1.20 per Share, vs. FactSet Est of $0.95

BioMarin Pharmaceutical Inc. (BMRN) reported Q2 adjusted EPS of $1.20 per share, surpassing the FactSet estimate of $0.95. The company also announced Q2 revenue of $990.0 million, exceeding the FactSet estimate of $932.0 million, and provided updated earnings guidance for the full year 2026. …

BioMarin earnings on deck as flagship drug faces competition

BioMarin Pharmaceutical Inc. is set to report second-quarter earnings, with analysts expecting 95 cents per share on $939.2 million in revenue, an increase from the previous quarter. The upcoming earnings call will likely focus on the competitive landscape for its top drug, VOXZOGO, which …